Average Insider

Where insiders trade, we follow

$ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Healthcare
Sector
Drug Manufacturers - General
Industry
Robert A. Michael
CEO
55000
Employees
$294.67
Current Price
$396.51B
Market Cap
52W Low$190.75
Current$294.6792.6% above low, 7.4% below high
52W High$302.93

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00--All Sells
Sells11$11,925,738.4040,619
1 monthBuys00--All Sells
Sells11$11,925,738.4040,619
2 monthsBuys00--All Sells
Sells11$11,925,738.4040,619
3 monthsBuys00--All Sells
Sells11$11,925,738.4040,619
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 9, 2026
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Sale40,619$293.60$11,925,738.40View Details
6 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
Feb 3, 2027
EPS
Estimated$3.89
ActualN/A
Revenue
Estimated$18.34B
ActualN/A

Past Earnings

Historical earnings results
Oct 30, 2026
EPS
Estimated$3.73
Actual$3.82
Beat
Revenue
Estimated$17.32B
Actual$17.40B
Beat
7 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.10.12